Immix Biopharma, Inc.
IMMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873835
No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Immix Biopharma, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 18 | 16 | −2 |
| Shares | 656.1K | 405.1K | −251.0K (−38.3%) |
| Value | $1.75M | $1.39M | −$361.7K (−20.7%) |
New holders (3)
Institutions that held Immix Biopharma, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Tocqueville Asset Management L.P. | 12,000 | $41.0K | 0.00% |
| Morgan Stanley | 400 | $1.37K | 0.00% |
| JPMorgan Chase & Co | 7 | $24 | 0.00% |
Sold out (5)
Institutions that held Immix Biopharma, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Lynwood Capital Management Inc. | 200,250 | $538.7K |
| Umb Bank N A | 72,639 | $195.4K |
| Renaissance Technologies LLC | 10,600 | $29.0K |
| Parallel Advisors, LLC | 2,890 | $7.77K |
| Tower Research Capital LLC (TRC) | 120 | $323 |